Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA:688266)
China
· Delayed Price · Currency is CNY 91.39
-1.81 (-1.94%)
May 14, 2025, 2:45 PM CST
SHA:688266 Revenue
Suzhou Zelgen Biopharmaceuticals had revenue of 167.64M CNY in the quarter ending March 31, 2025, with 54.87% growth. This brings the company's revenue in the last twelve months to 592.35M, up 53.23% year-over-year. In the year 2024, Suzhou Zelgen Biopharmaceuticals had annual revenue of 532.95M with 37.91% growth.
Revenue (ttm)
592.35M
Revenue Growth
+53.23%
P/S Ratio
41.58
Revenue / Employee
684.32K
Employees
867
Market Cap
24.67B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |